Evidence map›Paper›PMID 38864881›Full record

ReviewJournal of neurology2024

Myasthenia gravis due to anti-PD-1 treatment for an advanced colon cancer patient: a case report and literature review.

Hansong Yu, Xiaoxiao Wang, Yuetong Pan, Hongyan Li

Abstract readCase ReportsReview
PubMed Publisher
In one paragraph

Review in Journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hansong YuGeneral Surgery Department, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China.
Xiaoxiao WangGeneral Surgery Department, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China.
Yuetong PanGeneral Surgery Department, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China.
Hongyan LiGeneral Surgery Department, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China. hongyanli@xwhosp.org.ORCID http://orcid.org/0000-0002-2275-5039

Funding

National Natural Science Foundation of China 82271373Natural Science Foundation of Beijing Municipality 7232075
6 · The paper itself

Abstract

With the advancement of cancer treatment technologies, immunotherapy has begun to be widely utilized. Colon cancer is one of the most common types of cancer, with metastasis being a frequent occurrence in late-stage patients. Hence, immunotherapy, as an emerging and potentially effective treatment modality, merits exploration to enhance patient survival rates and clinical benefits. However, various immune-related adverse events cannot be entirely avoided. Myasthenia gravis induced by immunotherapy serves as a rare but potentially lethal adverse event, and it has been increasingly reported. Understanding the mechanisms of irAEs can aid in controlling the side effects induced by treatment. Here, we reported a case of myasthenia gravis occurring after anti-PD-1 therapy for late-stage colon cancer.

Indexed as

Colonic NeoplasmsImmune Checkpoint InhibitorsMyasthenia GravisAgedAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalHumansMaleProgrammed Cell Death 1 ReceptorAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalImmune Checkpoint InhibitorspembrolizumabProgrammed Cell Death 1 ReceptorColon cancerImmune checkpoint inhibitorMyasthenia gravisPD-1

Identifiers

PMID38864881

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.